Concepedia

John Lowe

JL

88

Publications

7K

Citations

46

H-Index

1964

Active since

Affiliations

Pfizer (United States)(Current)

Virginia Commonwealth University Medical Center

The University of Melbourne

University of Oxford

Vanderbilt University

John Lowe is an author at Pfizer (United States) specializing in medicine, pharmacology, and neuropharmacology.

ORCID

Top concepts

Publications per year

1964–2022

88

Publications

88

A Potent Nonpeptide Antagonist of the Substance P (NK <sub>1</sub> ) Receptor

R. Michael Snider, Jay W. Constantine, John Lowe et al. · Science · 1991 · 864 citations

, , +12

In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.

David M. Compton, Mario D. Aceto, John Lowe et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 358 citations

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.

Thomas Seeger, P A Seymour, Anne W. Schmidt et al. · Journal of Pharmacology and Experimental Therapeutics · 1995 · 320 citations

To Wake the Nations: Race in the Making of American Literature.

John Lowe, Eric J. Sundquist · The William and Mary Quarterly · 1994 · 231 citations

, , +12

Activity and Distribution of Binding Sites in Brain of a Nonpeptide Substance P (NK <sub>1</sub> ) Receptor Antagonist

Stafford McLean, Alan H. Ganong, Thomas Seeger et al. · Science · 1991 · 218 citations

, , +18

Rows per page

1–5 of 88